Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H25ClN2O3 |
Molecular Weight | 388.888 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3
InChI
InChIKey=ZKLPARSLTMPFCP-OAQYLSRUSA-N
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
CNS Activity
Sources: http://www.medscape.com/viewarticle/724851_3https://www.ncbi.nlm.nih.gov/pubmed/18781943
Curator's Comment: Levocetirizine is highly (91–93%) protein bound. It can cross the blood-brain barrier, but typically occupy only 30–50% of the H1 receptors in the cerebral cortex, compared to more than 90% of peripheral H1 receptors
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18336052 |
3.0 nM [Ki] | ||
Target ID: CHEMBL231 |
6.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | XYZAL Approved UseLevocetirizine dihydrochloride tablet is a histamine H1-receptor antagonist indicated for: The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) 1.1 Seasonal Allergic Rhinitis Levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 1.2 Perennial Allergic Rhinitis Levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. 1.3 Chronic Idiopathic Urticaria Levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. Launch Date2007 |
|||
Palliative | XYZAL Approved UseLevocetirizine dihydrochloride tablet is a histamine H1-receptor antagonist indicated for: The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) 1.1 Seasonal Allergic Rhinitis Levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 1.2 Perennial Allergic Rhinitis Levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. 1.3 Chronic Idiopathic Urticaria Levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. Launch Date2007 |
|||
Palliative | XYZAL Approved UseLevocetirizine dihydrochloride tablet is a histamine H1-receptor antagonist indicated for: The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) 1.1 Seasonal Allergic Rhinitis Levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 1.2 Perennial Allergic Rhinitis Levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. 1.3 Chronic Idiopathic Urticaria Levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. Launch Date2007 |
|||
Primary | XYZAL Approved UseFor the temporary relief of nasal decongestiom due to the commomn cold, hay fever or other upper respiratpry allergies. Temporarily relieves nasal stuffiness. Decongests nasal passages: shrinks swollen membranes. Temporarily restores freer breathing through the nose. Helps decongest sinus openings and passages; temporarily relieves sinus congestion and pressure. Promotes nasal and/or sinus drainage. temporarily relieves sinus congestion and pressure. Launch Date2007 |
|||
Primary | XYZAL Approved UseFor the temporary relief of nasal decongestiom due to the commomn cold, hay fever or other upper respiratpry allergies. Temporarily relieves nasal stuffiness. Decongests nasal passages: shrinks swollen membranes. Temporarily restores freer breathing through the nose. Helps decongest sinus openings and passages; temporarily relieves sinus congestion and pressure. Promotes nasal and/or sinus drainage. temporarily relieves sinus congestion and pressure. Launch Date2007 |
|||
Primary | XYZAL Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.17 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.27 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
512.25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11564134 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.97 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.31 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4136.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11564134 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11564134 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11758635 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOCETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18–60 years n = 13 Health Status: unhealthy Condition: severe urticaria Age Group: 18–60 years Population Size: 13 Sources: |
|
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, 48-64 years n = 2 Health Status: unhealthy Condition: chronic urticaria Age Group: 48-64 years Sex: M Population Size: 2 Sources: |
Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (2 patients) Sources: |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 428 Health Status: unhealthy Age Group: > 12 years Sex: M+F Population Size: 428 Sources: |
Disc. AE: Somnolence, Fatigue... AEs leading to discontinuation/dose reduction: Somnolence (2.3%) Sources: Fatigue (2.3%) Asthenia (2.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hepatotoxicity | 2 patients Disc. AE |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, 48-64 years n = 2 Health Status: unhealthy Condition: chronic urticaria Age Group: 48-64 years Sex: M Population Size: 2 Sources: |
Asthenia | 2.3% Disc. AE |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 428 Health Status: unhealthy Age Group: > 12 years Sex: M+F Population Size: 428 Sources: |
Fatigue | 2.3% Disc. AE |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 428 Health Status: unhealthy Age Group: > 12 years Sex: M+F Population Size: 428 Sources: |
Somnolence | 2.3% Disc. AE |
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, > 12 years n = 428 Health Status: unhealthy Age Group: > 12 years Sex: M+F Population Size: 428 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=20 Page: 20.0 |
likely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=20 Page: 20.0 |
likely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=20 Page: 20.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=20 Page: 20.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=20 Page: 20.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=20 Page: 20.0 |
weak | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022064s000_ClinPharmR.pdf#page=19 Page: 19.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 107.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Efficacy and safety of levocetirizine in seasonal allergic rhinitis. | 2001 |
|
Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. | 2002 Aug |
|
Comparative pharmacology of H1 antihistamines: clinical relevance. | 2002 Dec 16 |
|
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. | 2002 Feb |
|
Antihistamines in late-phase clinical development for allergic disease. | 2002 Feb |
|
Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). | 2002 Feb |
|
The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health. | 2002 Jun |
|
Chronic urticaria: a role for newer immunomodulatory drugs? | 2003 |
|
[H1 histamine antagonists]. | 2003 Apr |
|
Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. | 2003 Aug |
|
[Safety of new antihistamines]. | 2003 Jun |
|
[Clinical aspects of anti-inflammatory action of antihistamines]. | 2003 Jun |
|
Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. | 2003 Mar |
|
Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics. | 2003 May 30 |
|
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. | 2003 Oct |
|
Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. | 2003 Oct 1 |
|
Recovery of nitric oxide from acetylcholine-mediated vasodilatation in human skin in vivo. | 2004 Apr-May |
|
Antihistamines: do they work? Further well-controlled trials involving larger samples are needed. | 2004 Aug |
|
Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). | 2004 Feb |
|
Levocetirizine: the allergist's arsenal grows larger. | 2004 Jul |
|
Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. | 2004 Jul |
|
Gateways to clinical trials. | 2004 Mar |
|
Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. | 2004 Mar |
|
Gateways to clinical trials. | 2004 Nov |
|
Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. | 2004 Nov-Dec |
|
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. | 2004 Oct |
|
A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. | 2005 Aug |
|
Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. | 2005 Aug |
|
Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. | 2005 Dec |
|
Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. | 2005 Jan |
|
A treatment for allergic rhinitis: a view on the role of levocetirizine. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. | 2005 Mar |
|
Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. | 2005 May |
|
Bacillus clausii effects in children with allergic rhinitis. | 2005 May |
|
Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. | 2005 Sep |
|
Effect of levocetirizine on the contraction induced by histamine on isolated rabbit bronchioles from precision-cut lung slices. | 2006 |
|
Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. | 2006 |
|
Familial aquagenic urticaria and bernard-soulier syndrome. | 2006 |
|
Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine. | 2006 Aug |
|
Gateways to clinical trials. | 2006 Jun |
|
Chiral separation of cetirizine by capillary electrophoresis. | 2006 Jun |
|
Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. | 2006 Mar |
|
Gateways to clinical trials. | 2006 May |
|
Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. | 2006 May |
Patents
Sample Use Guides
Adults and children 12 years of age and older: 5 mg once daily in the evening. Children 6 to 11 years of age: 2.5 mg once daily in the evening. Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution)[2.5mL] once daily in the evening.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16120090
Eosinophils isolated from normal subjects were pre-incubated with a concentration range of levocetirizine (10(-6)-10(-10) m) or negative dilution control. Levocetirizine significantly inhibited resting eosinophil adhesion to recombinant human vascular cell adhesion molecule-1 (rhVCAM-1) with maximal effect at 10(-8) M with an EC(50) of 10(-9) m.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R06AE09
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
||
|
WHO-VATC |
QR06AE09
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
||
|
NDF-RT |
N0000175587
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
||
|
NDF-RT |
N0000000190
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
||
|
LIVERTOX |
551
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092505
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
Levocetirizine
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
356887
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
130018-77-8
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
7700
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
6U5EA9RT2O
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
LEVOCETIRIZINE
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
C66008
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201191
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
DB06282
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
TT-54
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
SUB08467MIG
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
6U5EA9RT2O
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
C472067
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
m3291
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
1214
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
1549000
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
DTXSID60156294
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY | |||
|
1566
Created by
admin on Fri Dec 15 15:35:23 GMT 2023 , Edited by admin on Fri Dec 15 15:35:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)